# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

> **NCT03102489** · PHASE1 · COMPLETED · sponsor: **Ivix LLX** · enrollment: 18 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder(HSDD)

## Interventions

- **DRUG:** BP101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03102489
- **Lead sponsor:** Ivix LLX
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-22
- **Primary completion:** 2017-06-21
- **Final completion:** 2017-09-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03102489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03102489, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03102489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*